| 1 |
Yao Y, Zhang J, Li X, Zao X, Cao X, Chen G, Ye Y. Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis. Front Public Health 2022;10:1037527. [PMID: 36407996 DOI: 10.3389/fpubh.2022.1037527] [Reference Citation Analysis]
|
| 2 |
Tseng C, Chen T, Wu J, Lee T, Borghi JA, Lin J, Nguyen MH, Hsu Y. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100617] [Reference Citation Analysis]
|
| 3 |
Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2022;71:1629-41. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 4 |
van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 5 |
Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021;13:1042-57. [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Chen H, Ding X, Liao G, Xia M, Ren Z, Fan R, Peng J. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B. J Viral Hepat 2021;28:1121-9. [PMID: 33899998 DOI: 10.1111/jvh.13526] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Jeng WJ, Liaw YF. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Semin Liver Dis 2021;41:349-57. [PMID: 34182587 DOI: 10.1055/s-0041-1729973] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 8 |
Cheng Y, Ji Y, Duan H, Li Y, Lau G, Wang F. What Should Be Done to Re-evaluate Cessation of Nucleos(t)ide Analog Therapy for Chronic Hepatitis B Infection? Infectious Diseases & Immunity 2021;1:93-102. [DOI: 10.1097/id9.0000000000000014] [Reference Citation Analysis]
|
| 9 |
Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 10 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 12 |
Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 13 |
Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 14 |
Papatheodoridi M, Papatheodoridis G. Can we stop nucleoside analogues before HBsAg loss? J Viral Hepat 2019;26:936-41. [PMID: 30803099 DOI: 10.1111/jvh.13091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 15 |
Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:697-709. [PMID: 30702196 DOI: 10.1111/jvh.13068] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 16 |
Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Cancer Biomark. 2018;23:235-242. [PMID: 30103302 DOI: 10.3233/cbm-181402] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 18 |
Marciano S, Gadano A. Why not to stop antiviral treatment in patients with chronic hepatitis B. Liver Int 2018;38 Suppl 1:97-101. [PMID: 29427480 DOI: 10.1111/liv.13627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 19 |
van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018;38 Suppl 1:90-6. [PMID: 29427489 DOI: 10.1111/liv.13654] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 20 |
Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines 2018. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 21 |
Chen CH, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2018;24:997-1003. [PMID: 29288020 DOI: 10.1016/j.cmi.2017.12.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 22 |
Hung CH, Wang JH, Lu SN, Hu TH, Lee CM, Chen CH. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat 2017;24:599-607. [PMID: 28130815 DOI: 10.1111/jvh.12683] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 23 |
Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci Rep 2017;7:1839. [PMID: 28500322 DOI: 10.1038/s41598-017-02010-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 24 |
Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B. Korean J Gastroenterol. 2016;67:28-34. [PMID: 26809629 DOI: 10.4166/kjg.2016.67.1.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 25 |
Wang CC, Tseng KC, Hsieh TY, Tseng TC, Lin HH, Kao JH. Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. Am J Gastroenterol 2016;111:1286-94. [PMID: 27045923 DOI: 10.1038/ajg.2016.109] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 26 |
Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016;63:1481-92. [PMID: 27100145 DOI: 10.1002/hep.28438] [Cited by in Crossref: 184] [Cited by in F6Publishing: 189] [Article Influence: 26.3] [Reference Citation Analysis]
|
| 27 |
Ray G. 5-year efficacy of entecavir in Indian patients with chronic hepatitis B. Indian J Gastroenterol 2016;35:190-4. [PMID: 27216583 DOI: 10.1007/s12664-016-0664-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 28 |
Lu J, Li J, Liu Y, Ren S, Cao Z, Jin Y, Ma L, Shen C, Chen X. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. PLoS One 2015;10:e0141072. [PMID: 26524467 DOI: 10.1371/journal.pone.0141072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 29 |
Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther 2015;42:1182-91. [PMID: 26381928 DOI: 10.1111/apt.13409] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 30 |
Qiu YW, Huang LH, Yang WL, Wang Z, Zhang B, Li YG, Su TT, Zhou HY, Xu W, Wang XD, Dai YP, Gan JH. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016;43:43-8. [PMID: 26523639 DOI: 10.1016/j.ijid.2015.10.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 31 |
Chen L, Gan QR, Zhang DQ, Yao LF, Lin RS, Li Q, Lin MH, Yu DM, Zhang XX, Pan C. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:201-7. [PMID: 26493847 DOI: 10.1016/j.cmi.2015.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 32 |
Tsai DS, Huang MH, Chang YS, Li TC, Peng WH. The use of Chinese herbal medicines associated with reduced mortality in chronic hepatitis B patients receiving lamivudine treatment. J Ethnopharmacol 2015;174:161-7. [PMID: 26277491 DOI: 10.1016/j.jep.2015.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 33 |
Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015;42:243-57. [PMID: 26151841 DOI: 10.1111/apt.13272] [Cited by in Crossref: 95] [Cited by in F6Publishing: 68] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 34 |
Xie QL, Zhu Y, Wu LH, Fu LL, Xiang Y. The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. PLoS One. 2015;10:e0132219. [PMID: 26226455 DOI: 10.1371/journal.pone.0132219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 35 |
Ge GH, Ye Y, Zhou XB, Chen L, He C, Wen DF, Tan YW. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients. World J Gastroenterol 2015; 21(28): 8653-8659 [PMID: 26229407 DOI: 10.3748/wjg.v21.i28.8653] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 36 |
Clevudine/entecavir/lamivudine. Reactions Weekly 2015;1554:67-67. [DOI: 10.1007/s40278-015-2134-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 37 |
Kranidioti H, Manolakopoulos S, Khakoo SI. Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. Ann Gastroenterol 2015;28:173-81. [PMID: 25831071] [Reference Citation Analysis]
|
| 38 |
Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int 2015;35 Suppl 1:82-90. [PMID: 25529092 DOI: 10.1111/liv.12735] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
|
